Safe, effective and oral antiparasitics against protozoal infections
The purine nucleoside platform is based on known and novel sugar- and purine ring scaffolds.
The nucleoside platform contains lead molecules for different indications. Proof of concept data at different stages (in vitro to in vivo) are available for various indications: Leishmania, Chagas, Nagana disease, Dourine, Surra, Blackhead, Cryptosporidium, and Toxoplasma species.
Proof of concept in various mouse models
As an example, we found 3’-deoxytubercidin analogues to be highly potent trypanocides against T. brucei spp. One analogue served as proof-of-concept in relevant mouse model of T. brucei infection. This derivative, 3’-deoxytubercidin, displays curative activity in both acute and CNS-stage infection in mice, highlighting that it is able to cross the blood-brain-barrier, likely a class effect.
A purine nucleoside platform with the ability to act as antiprotozoal agents
· Contact name
Sven Arnouts
· E-mail
sven.arnouts@ugent.be
· Phone
+32 495 707 334
· Partner sought:
Partnering
We seek development and marketing partners interested in developing nucleoside analogues as anti-parasitic against protozoal infections.
Sven Arnouts
sven.arnouts@ugent.be
+32 495 707 334
en
ES